Search Results
Your search for ,HIS matches 4425 pages
Showing 4351 - 4400Audit of NHS Breast Cancer Screening Programme Reveals Significant Variations Between Hospitals in Treatment Outcomes for DCIS
Analysis of data from the UK NHS Breast Screening Programme has shown significant variations in the outcomes of treatment for women with ductal carcinoma in situ (DCIS) between UK hospitals. Dr. Jeremy Thomas, a consultant pathologist at the Western General Hospital, Edinburgh, told the 9th...
Harms Outweigh Benefits for Women Aged 70 and Over in National Breast Cancer Screening Programs
Extending national breast cancer screening programs to women over the age of 70 does not result in a decrease in the number of cancers detected at advanced stages, according to new research from The Netherlands. Instead, researchers told attendees at the 9th European Breast Cancer Conference that...
Genetic Testing May Improve Selection of Women With Estrogen Receptor–Positive Breast Cancer for 10 vs 5 Years of Hormonal Therapy
Genetic analyses of results from 1,125 postmenopausal women being treated for estrogen-responsive breast cancer have shown that some of them are more likely than others to have a late recurrence of their cancer and might benefit from 10 years of hormone therapy rather than 5 years. Women who had...
American Association for Cancer Research Elects José Baselga, MD, PhD, as President-Elect 2014-2015
The members of the American Association for Cancer Research (AACR) have elected José Baselga, MD, PhD, Physician-in-Chief at Memorial Sloan Kettering Cancer Center in New York, as their President-Elect for 2014–2015. Dr. Baselga is an internationally recognized physician-scientist...
Study Finds CT Scans Predict Chemotherapy Response in Pancreatic Cancer
Computed tomography (CT) scans routinely taken to guide the treatment of pancreatic cancer may provide an important secondary benefit. According to new research published in the Journal of Clinical Investigation by Koay et al, the scans also reflect how well chemotherapy will penetrate the tumor,...
Yoga Regulates Stress Hormones and Improves Quality of Life for Women With Breast Cancer Undergoing Radiation Therapy
For women with breast cancer undergoing radiation therapy, yoga offers unique benefits beyond fighting fatigue, according to a study by Chandwani et al published in the Journal of Clinical Oncology. While simple stretching activities counteracted fatigue, patients who participated in yoga exercises ...
African Americans Have Higher Prevalence of Multiple Myeloma Precursor Than Whites and Hispanics
A large population-based study by Landgren et al has found that African Americans are more likely to have a higher prevalence of monoclonal gammopathy of undetermined significance (MGUS), a precursor to the development of multiple myeloma, compared with whites or Hispanics. The study is published...
Oropharyngeal Cancer Patients Report Benefit in Salivary Function With Reduction of Radiation Dose to Bilateral Submandibular Lymph Nodes
For head and neck cancer patients undergoing radiation therapy, a reduction in the amount of radiation treatment volume to the submandibular (level IB) lymph nodes resulted in better patient-reported salivary function, according to research presented today at the 2014 Multidisciplinary Head and...
Avoiding Radiation to Major Salivary Glands in Head and Neck Cancer Is Safe and Improves Quality of Life
New research is showing that sparing the contralateral submandibular gland during radiation therapy in the treatment of locally advanced head and neck cancer is technically feasible and safe even in advanced-stage, node-positive disease and base-of-tongue lesions. Limiting radiation to these major...
Biomarker May Predict Response to Ipilimumab in Advanced Melanoma
Among patients with advanced melanoma, presence of higher levels of the protein vascular endothelial growth factor (VEGF) in blood was associated with poor response to treatment with the immunotherapy ipilimumab (Yervoy), according to a study by Yuan et al published in Cancer Immunology Research....
ASCO Issues New Recommendations for Family History-Taking in Oncology Setting
When oncologists see a new patient, they should emphasize careful documentation of first- and second-degree cancer family history, according to new recommendations published by the American Society of Clinical Oncology. The recommendations are the first to focus on family history-taking...
Study Reports Success in Targeted Therapy for Lung Adenocarcinoma
The most common genetic subtype of lung cancer, which has long defied treatment with targeted therapies, has had its growth halted by a combination of two already-in-use drugs in laboratory and animal studies, setting the stage for clinical trials of the drugs in patients. The study, published in...
New Clues May Link Hereditary Cancer Genes to Increased Risk of Cancer From Alcohol
In laboratory experiments conducted on human cell lines at the Johns Hopkins Sidney Kimmel Cancer Center, scientists have shown that people carrying certain mutations in two hereditary cancer genes, BRCA2 and PALB2, may have a higher than usual susceptibility to DNA damage caused by acetaldehyde, a ...
Study Questions the Anticancer Mechanism of Metformin
The drug metformin, which is approved for the treatment of type 2 diabetes, has been tested in clinical trials as a tumor suppressor in different cancers due to its role in activating the AMPK signaling pathway. However, a new study by Liu et al published in Proceedings of the National Academy of...
Multiple Myeloma Study Shows Widespread Genetic Heterogeneity
A detailed study of tissue samples from more than 200 patients with multiple myeloma has found that an individual patient’s tumor can harbor populations of cancer cells equipped with different mutations. The result could have therapeutic ramifications for future patients, according to study...
Recurrent Ovarian Cancers Respond to Cancer Vaccine After ‘Reprogramming’ With Decitabine
Treatment with the drug decitabine prior to administration of chemotherapy and a cancer vaccine yielded clinical benefit for women with recurrent ovarian cancer, suggesting that this combinatorial chemoimmunotherapy may provide a new treatment option for patients with the disease, according to a...
Science Magazine Names Cancer Immunotherapy as Scientific Breakthrough of the Year
While acknowledging that the full potential of cancer immunotherapy remains unclear, the editors of the journal Science said that the approach of using the immune system to attack tumors marks a turning point in the treatment of cancer. The successes of cancer immunotherapy in clinical trials in...
CALGB 40603 Trial Supports Adding Carboplatin to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
The addition of carboplatin to a neoadjuvant regimen significantly increased the rate of pathologic complete response in patients with triple-negative breast cancer. The results from the CALGB/Alliance 40603 study were reported at the 2013 San Antonio Breast Cancer Symposium (Abstract S5-01)....
Tasquinimod May Improve Survival in Men With Metastatic Prostate Cancer
An investigational prostate cancer treatment slows the disease’s progression and may increase survival, especially among men whose cancer has spread to the bones, according an analysis led by the Duke Cancer Institute. The study, published in the journal Clinical Cancer Research, adds...
Study Explains Cyclophosphamide’s Role in Preventing Graft-vs-Host Disease
Results of a Johns Hopkins study may explain why cyclophosphamide prevents graft-vs-host disease in people who receive bone marrow transplants. The experiments point to an immune system cell that evades the toxic effects of cyclophosphamide and protects patients from a lethal form of graft-vs-host...
New Mutation Found in the Estrogen Receptor May Cause Resistance to Breast Cancer Treatment
Most patients with estrogen receptor–positive metastatic breast cancer who initially respond to endocrine treatments will eventually develop resistance to the therapies. A study by Ido Wolf, MD, Head of the Oncology Department at the Tel Aviv Sourasky Medical Center in Israel, and colleagues...
Long-Distance Travel for Cancer Care Is Linked to Later-Stage Breast Cancer Diagnosis
The longer a woman with breast cancer has to travel to reach a comprehensive cancer center, the more likely she is to have later-stage disease at diagnosis, and the more likely she is to have a mastectomy, according to study by medical student Krishan Jethwa and colleagues from the University of...
Investigational Antibody-Drug Conjugate May Provide New Treatment Option for Pancreatic Cancer Patients
Patients with pancreatic cancer may benefit from an investigational member of an emerging class of anticancer drugs called antibody-drug conjugates, according to preclinical results presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held October...
Researchers Identify Four Genetic Variants Linked to Esophageal Cancer and Barrett’s Esophagus
An international consortium co-led by researchers at Fred Hutchinson Cancer Research Center and the QIMR Berghofer Medical Research Institute in Australia has identified four genetic variants associated with an increased risk of esophageal cancer and its precursor, Barrett’s esophagus. The...
ECC 2013: PI3KCA-Mutant Tumors Not Likely to Respond to Neoadjuvant HER2 Blockade
In patients with early breast cancer receiving anti-HER2 therapy in the NeoALTTO trial, mutations in PIK3CA were associated with lower rates of pathologic complete response, Jose Baselga, MD, reported at the European Cancer Congress 2013 (Abstract 1859) in Amsterdam. In patients treated with the...
ECC 2013: Radiation to Chest Lymph Nodes Improves Survival in Early Breast Cancer
Extending radiation to the lymph nodes behind the sternal wall and above the collarbone extends overall survival in patients with stage I to III breast cancer and does not increase toxicity compared to conventional locoregional radiation therapy, according to 10-year results of an international...
ECC 2013: Molecular Sequencing Identifies Drug Targets for Cancers of Unknown Primary Origin
Cancers of unknown primary origin pose a treatment dilemma for oncologists and a great deal of anxiety for patients and their families. A study reported at the European Cancer Congress 2013 in Amsterdam (Abstract LBA39) shows that molecular profiling can identify targetable mutations in up to 80%...
Telomere Length May Be a Prognostic Marker for Prostate Cancer
Cancer cells are known to have short telomeres, but just how short they are from cancer cell to cancer cell may be a determining factor in a prostate cancer patient's prognosis, according to a study led by scientists at Johns Hopkins. "Doctors are looking for new ways to accurately predict...
Breast Cancer Treatment in 10 Years: George Sledge, MD, Offers His Predictions
In a keynote lecture during the 2013 Breast Cancer Symposium breast cancer expert and ASCO Past President George Sledge, MD, offered five predictions for the future of the medical management of breast cancer. Dr. Sledge is now Chief of Oncology at Stanford University School of Medicine, Palo Alto,...
Researchers Uncover Genetic Cause of Childhood Acute Lymphoblastic Leukemia
For the first time, a genetic link specific to risk of childhood leukemia has been identified, according to a team of researchers from Memorial Sloan-Kettering Cancer Center, St. Jude Children’s Research Hospital, University of Washington, and other institutions. The discovery was reported...
Majority of Breast Cancer Deaths Occur in Younger, Unscreened Women, Study Finds
A new analysis has found that most deaths from breast cancer occur in younger women who do not receive regular mammograms. Published early online in Cancer, the study indicates that regular screening before age 50 should be encouraged. The use of mammograms to prevent breast cancer deaths has been ...
First-Line Brivanib Not Noninferior to Sorafenib in Advanced Hepatocellular Carcinoma
The investigational drug brivanib is a dual inhibitor of VEGF and fibroblast growth factor signaling, both implicated in hepatocellular carcinoma. In a noninferiority trial (BRISK-FL) reported in Journal of Clinical Oncology, Philip J. Johnson, MD, of the Institute of Translational Medicine,...
High-Tech Imaging Contributes to Overdiagnosis, Overtreatment of Low-Risk Thyroid Cancers
A study from the Mayo Clinic Center for the Science of Health Care Delivery finds that advances in imaging technologies, including ultrasound, computed tomography (CT), and magnetic resonance imaging (MRI), are fueling an epidemic in the diagnosis and treatment of thyroid cancers that are unlikely...
Many Patients With Head and Neck Cancer Report Being Depressed, But Few Use Mental Health Services
Despite a relatively high rate of depression among patients with head and neck cancer following radiation therapy, mental health services were severely underutilized in this group, concluded researchers who analyzed questionnaire results from 211 patients. The patients had been previously treated...
New MRI Technique Reveals Brain Tumor Response to Antiangiogenesis Therapy
A new way of analyzing data acquired in magnetic resonance imaging (MRI) appears to be able to identify whether or not tumors are responding to antiangiogenesis therapy, which may help physicians determine the most appropriate treatments for patients. In a report published online in Nature...
Study Suggests Neural Stem Cells May Regenerate After Radiation Therapy
Scientists have long believed that healthy brain cells, once damaged by radiation designed to kill brain tumors, cannot regenerate. But new research in mice suggests that neural stem cells, the body's source of new brain cells, are resistant to radiation, and can be roused from a hibernation-like...
Burkitt Lymphoma Survival Outcomes Improve for Younger Patients
According to a new study published in the journal Cancer, the survival outcome of patients with Burkitt lymphoma has improved substantially over the past decade, with notable exceptions. To help doctors and researchers better understand who responds well to treatment and who does not, the study...
Researchers Identify Gene Variations in Lung Cancer Patients That May Help Predict an Individual’s Treatment Response
Researchers at the Moffitt Cancer Center have identified four inherited genetic variants in patients with non–small cell lung cancer that can help predict survival and treatment response. Their findings, published in Carcinogenesis, could help lead to more personalized treatment options and...
Blocking Sugar Intake May Reduce Cancer Risk or Progression in Certain Malignant Tumors
Blocking dietary sugar and its activity in tumor cells may reduce cancer risk and progression, according to researchers from the Icahn School of Medicine at Mount Sinai in New York. The study, conducted in fruit flies and published in the August issue of Cell, provides insight as to why...
Researchers Uncover How a Potent Compound Kills Prostate Cancer Cells
A new study led by researchers at Sanford-Burnham Medical Research Institute reveals how a promising anticancer compound called SMIP004 specifically kills prostate cancer cells by compromising their ability to withstand environmental stress. The study, recently published in Oncotarget, uncovered...
Benefit Seen with Both Autologous and Allogeneic Hematopoietic Cell Transplantation in T-cell Non-Hodgkin Lymphoma
In a report in Journal of Clinical Oncology, Sonali M. Smith, MD, of University of Chicago Hospitals, and colleagues analyzed outcomes in a large cohort of autologous or allogeneic hematopoietic cell transplantation recipients with the most common T-cell non-Hodgkin lymphoma histologies. Their ...
Richard I. Fisher, MD, Named President and CEO of Fox Chase Cancer Center
Richard I. Fisher, MD, a leading cancer center administrator and nationally recognized hematology/oncology expert, has been appointed President and CEO of Fox Chase Cancer Center. Dr. Fisher will also hold the title of Cancer Center Director of Fox Chase, serving as the principal investigator on...
Study Suggests Proteins Involved in Immunity May Be Responsible for Cancer-causing Mutations
A set of proteins involved in the body’s natural defenses produces a large number of mutations in human DNA, according to a study led by researchers at the National Institutes of Health. The findings, published in Nature Genetics, suggest that these naturally produced mutations are just as...
Whole-exome Sequencing of the NCI-60 Cell Line Panel Provides a Genomic Resource for Cancer Biology and Systems Pharmacology
The NCI-60 cell lines, which represent cancers of lung, colon, brain, ovary, breast, prostate, and kidney as well as leukemia and melanoma, are the most frequently studied human tumor cell lines in cancer research and have generated the most extensive cancer pharmacology database worldwide. As...
Critical Pathway in Cell Cycle May Lead to Cancer Development
A team of scientists at the Salk Institute for Biological Studies has identified why disruption of a vital pathway in cell cycle control leads to the proliferation of cancer cells. Their findings on telomeres, published today in Molecular Cell, suggest a potential target for preventive measures...
Technologies for Monitoring Minimal Residual Disease May Help Predict Outcomes for Patients with Leukemia
New evidence suggests that using advanced genetics technologies to monitor for remaining cancer cells after treatment may soon become an effective tool to inform treatment decisions and ultimately predict patient outcomes for patients with a particularly aggressive form of acute lymphocytic...
Two HIV Patients Show No Signs of Disease Following Bone Marrow Transplants for Hodgkin Lymphoma
Timothy Henrich, MD, Associate Physician in the Division of Infectious Disease at Brigham and Women’s Hospital in Boston, reported that two patients with long-standing HIV infections have no detectable levels of the disease in their blood cells, even though they stopped taking their...
Crizotinib Improves Progression-free Survival vs Pemetrexed or Docetaxel in Advanced ALK-positive NSCLC
In a phase III trial reported by Alice T. Shaw, MD, PhD, of Massachusetts General Hospital, and colleagues in The New England Journal of Medicine, crizotinib (Xalkori) improved progression-free survival compared with standard chemotherapy in previously treated patients with advanced...
ASCO 2013: Genomic Heterogeneity Can Lead to the Selection of ‘Incorrect’ Targeted Inhibitors
Genomic heterogeneity within tumors and among lesions varies widely, and “discordance among lesions could lead to the selection of the ‘incorrect’ targeted inhibitor,” according to David B. Solit, MD, of Memorial Sloan-Kettering Cancer Center, who spoke at the ASCO/American...
Metabolic Molecule Drives Growth of High-grade Glioma
A study led by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) has identified an abnormal metabolic pathway that drives cancer cell growth in a particular glioblastoma...
